fbpx Skip to main content

The costs of treating wet age-related macular degeneration (AMD) are often very high, both at the individual and societal levels. This study focused on conducting a cost-benefit analysis of wet AMD treatment to understand the economic impact of these treatments. The study specifically compares three types of treatments: intravitreal bevacizumab, ranibizumab, and aflibercept.

The study relied on past clinical trials and available Medicare data. A total of 168,400 patients were estimated to have new-onset AMD. The cost-benefit analysis used 2018 dollars. The analysis compared the 11-year costs of bevacizumab, ranibizumab, and aflibercept monotherapies with the ophthalmic and nonophthalmic medical and nonmedical costs saved by the therapies.

Each monotherapy was concluded to collect a considerable return on investment for patients and insurers. Bevacizumab treatment was concluded to have the highest potential return on investment, at 2,421%. Of the $28.5 billion 11-year net societal gain resulting from wet AMD therapy, $24.2 billion was from bevacizumab treatment [1].

Source:

[1] Brown, G. C., Brown, M. M., Rapuano, S. B., & Boyer, D. (2021). A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. American Journal of Ophthalmology, 223, 405–429. https://doi.org/10.1016/j.ajo.2020.07.010

You May Also Like::  The Economic Value of Anti-VEGF Treatment for Wet AMD

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.

#dermtwitter
@AADmember

New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More